G1 Therapeutics Probability of Future Stock Price Finishing Over 5.03
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
GTHX |
G1 Therapeutics Target Price Odds to finish over 5.03
The tendency of GTHX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 5.03 in 90 days |
| 7.15 | 90 days | 5.03 | about 47.28 |
Based on a normal probability distribution, the odds of G1 Therapeutics to stay above $ 5.03 in 90 days from now is about 47.28 (This G1 Therapeutics probability density function shows the probability of GTHX Stock to fall within a particular range of prices over 90 days) . Probability of G1 Therapeutics price to stay between $ 5.03 and its current price of $7.15 at the end of the 90-day period is about 33.76 .
Given the investment horizon of 90 days G1 Therapeutics has a beta of 0.63. This usually indicates as returns on the market go up, G1 Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding G1 Therapeutics will be expected to be much smaller as well. Moreover G1 Therapeutics has an alpha of 1.5899, implying that it can generate a 1.59 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). G1 Therapeutics Price Density |
| Price |
Predictive Modules for G1 Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as G1 Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.G1 Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. G1 Therapeutics is not an exception. The market had few large corrections towards the G1 Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold G1 Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of G1 Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.59 | |
β | Beta against Dow Jones | 0.63 | |
σ | Overall volatility | 2.05 | |
Ir | Information ratio | 0.18 |
G1 Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of G1 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for G1 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
G1 Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GTHX Stock often depends not only on the future outlook of the current and potential G1 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. G1 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.7 M | |
| Cash And Short Term Investments | 82.2 M |
G1 Therapeutics Technical Analysis
G1 Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. GTHX Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of G1 Therapeutics. In general, you should focus on analyzing GTHX Stock price patterns and their correlations with different microeconomic environments and drivers.
G1 Therapeutics Predictive Forecast Models
G1 Therapeutics' time-series forecasting models is one of many G1 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary G1 Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about G1 Therapeutics
Checking the ongoing alerts about G1 Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for G1 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |